Avicanna talks medical pot real-world evidence study

Executive Summary

• Avicanna Inc. published peer-reviewed results from an investigator-led real-world evidence study evaluating patient-reported outcomes for chronic pain patients using physician-supervised medical cannabis via the MyMedi.ca platform.
• The 24-week observational study demonstrated statistically significant improvements in pain intensity, pain interference, anxiety, depressive symptoms, and overall quality of life, though the magnitude of change did not meet minimal clinically important difference thresholds.
• The findings highlight the value of clinician-supervised models for monitoring efficacy and safety, while underscoring the need for further placebo-controlled trials to optimize dosing and formulations; the study remains open for enrollment across seven Canadian provinces.

Key Details

• Study Design: Prospective, observational real-world evidence (MCRWE) study conducted through the MyMedi.ca platform.
• Lead Investigator: Dr. Hance Clarke, Director of Pain Services at University Health Network (UHN).
• Publication Venue: Peer-reviewed in the Canadian Journal of Pain.
• Follow-Up Period: 24 weeks.
• Primary Outcomes: Statistically significant improvements from baseline in pain interference, pain intensity, anxiety, depressive symptoms, and overall quality of life.
• Clinical Significance: Observed directional improvements align with existing real-world and clinical literature, though changes did not reach minimal clinically important difference thresholds.
• Study Status & Scope: Ongoing enrollment across seven Canadian provinces; targets chronic pain, sleep, anxiety, depression, and epilepsy.
• Secondary Objectives: Assessment of changes in concomitant medication use.
• Avicanna's Role: Provided patient support services, clinical infrastructure, and data coordination without influencing clinical decision-making or patient care.
• Next Steps: Highlights need for placebo-controlled randomized trials to define optimal dosing strategies, formulations, and routes of administration.

Notable Quotes

• Dr. Hance Clarke, Principal Investigator: "While the term 'medical cannabis' is widely used, this study specifically evaluated outcomes among patients using medical cannabis under the supervision of a health care provider... These findings support the potential role of medical cannabis in selected patients as indicated by preliminary real-world data, while highlighting the importance of clinician involvement in monitoring efficacy, safety and ongoing patient outcomes."
• Dr. Karolina Urban, EVP of Scientific and Medical Affairs, Avicanna: "This first peer-reviewed publication from our real-world evidence platform represents an important milestone... High-quality, prospective real-world data can play a critical role in complementing randomized clinical trials, informing clinical practice and supporting the responsible integration of cannabinoid-based medicines into evidence-based care."